GlaxoSmithKline plc (the 'Company')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Philip Hampton |
||||
b) |
Position/status |
Non-Executive Chairman |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2017-04-26 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Professor Sir Roy Anderson |
||||
b) |
Position/status |
Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2017-04-26 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr Vindi Banga |
||||
b) |
Position/status |
Senior Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information A ggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2017-04-26 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Dr Vivienne Cox |
||||
b) |
Position/status |
Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2017-04-26 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Ms Lynn Elsenhans |
||||
b) |
Position/status |
Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053 |
||||
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information A ggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2017-04-26 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Dr Jesse Goodman |
||||
b) |
Position/status |
Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053 |
||||
b) |
Nature of the transaction |
Dr Jesse Goodman was appointed to the Board with effect from 1 January 2016, as previously announced, and in accordance with the share allocation arrangements for Independent Non-Executive Directors, 25% of his fees were retained to be reinvested in notional ADSs at a date to be mutually agreed. The accumulated balance of the retained fees has now been reinvested as disclosed below. Going forward, notional ADSs of the Company will be allocated on a quarterly basis. Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2016 to 31 March 2017.
|
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2017-04-26 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Ms Judy Lewent |
||||
b) |
Position/status |
Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
American Depositary Shares ('ADSs')
ISIN: US37733W1053 |
||||
b) |
Nature of the transaction |
Acquisition of notional ADSs under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2017-04-26 |
||||
f) |
Place of the transaction
|
n/a |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Mr Urs Rohner |
||||
b) |
Position/status |
Independent Non-Executive Director |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GlaxoSmithKline plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 |
||||
b) |
Nature of the transaction |
Acquisition of notional Ordinary Shares under the share allocation arrangements for Independent Non-Executive Directors for the period of service from 1 January 2017 to 31 March 2017. |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
e) |
Date of the transaction |
2017-04-26 |
||||
f) |
Place of the transaction
|
n/a |